California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.
In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.
Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.
“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”
Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.
He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.